![IJMS | Free Full-Text | Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease IJMS | Free Full-Text | Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease](https://www.mdpi.com/ijms/ijms-25-00077/article_deploy/html/images/ijms-25-00077-g001.png)
IJMS | Free Full-Text | Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease
![A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond | EMBO Molecular Medicine A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/d80c4f28-0346-4eb9-a913-dad7e4c3e228/emmm202215997-fig-0003-m.png)
A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond | EMBO Molecular Medicine
![COVID: Nadir Arber, l'Israélien à l'origine de l'EXO-CD24, "médicament miracle" - The Times of Israël COVID: Nadir Arber, l'Israélien à l'origine de l'EXO-CD24, "médicament miracle" - The Times of Israël](https://static.timesofisrael.com/fr/uploads/2021/02/iStock-1205199983.jpg)
COVID: Nadir Arber, l'Israélien à l'origine de l'EXO-CD24, "médicament miracle" - The Times of Israël
![Spray nasal contra covid citado por Bolsonaro é um dos mais incipientes e não tem dado publicado | Brasil | Valor Econômico Spray nasal contra covid citado por Bolsonaro é um dos mais incipientes e não tem dado publicado | Brasil | Valor Econômico](https://s2-valor.glbimg.com/gYCrynbJFxad27jg7uw1tGgDbqI=/0x0:3506x2337/984x0/smart/filters:strip_icc()/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2021/l/M/FeqTZlR0iI0lPEmYBQSg/50980018066-b4c54f8a17-o.jpg)
Spray nasal contra covid citado por Bolsonaro é um dos mais incipientes e não tem dado publicado | Brasil | Valor Econômico
![Targeting CD24 as a novel immunotherapy for solid cancers | Cell Communication and Signaling | Full Text Targeting CD24 as a novel immunotherapy for solid cancers | Cell Communication and Signaling | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12964-023-01315-w/MediaObjects/12964_2023_1315_Fig2_HTML.png)
Targeting CD24 as a novel immunotherapy for solid cancers | Cell Communication and Signaling | Full Text
![Life | Free Full-Text | Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review Life | Free Full-Text | Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review](https://www.mdpi.com/life/life-12-01472/article_deploy/html/images/life-12-01472-g002.png)
Life | Free Full-Text | Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review
![IJMS | Free Full-Text | Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease IJMS | Free Full-Text | Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease](https://www.mdpi.com/ijms/ijms-25-00077/article_deploy/html/images/ijms-25-00077-g003.png)
IJMS | Free Full-Text | Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease
![A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond | EMBO Molecular Medicine A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/58892e9f-905a-4ee5-bdfd-de03dfa1b1ad/emmm202215997-fig-0001-m.png)
A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond | EMBO Molecular Medicine
![Likelihood of Approval and Phase Transition Success Rate Model - EXO-CD24 in Acute Respiratory Distress Syndrome - Market Research Reports & Consulting | GlobalData UK Ltd. Likelihood of Approval and Phase Transition Success Rate Model - EXO-CD24 in Acute Respiratory Distress Syndrome - Market Research Reports & Consulting | GlobalData UK Ltd.](https://www.globaldata.com/store/wp-content/uploads/sites/2/2023/07/reportcover-LG5.webp)
Likelihood of Approval and Phase Transition Success Rate Model - EXO-CD24 in Acute Respiratory Distress Syndrome - Market Research Reports & Consulting | GlobalData UK Ltd.
![Radio Cadena Voces on X: "#RCVInternacional El tratamiento, llamado EXO-CD24, es administrado directo a los pulmones para eliminar daños generados por covid Dato: 29 de 30 pacientes con COVID-19 en condición moderada Radio Cadena Voces on X: "#RCVInternacional El tratamiento, llamado EXO-CD24, es administrado directo a los pulmones para eliminar daños generados por covid Dato: 29 de 30 pacientes con COVID-19 en condición moderada](https://pbs.twimg.com/media/Eu1weFVWYAEJ-3A.jpg)